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Abstract
The simian immunodeficiency virus (SIV) challenge model of lentiviral infection is often
used as a model to human immunodeficiency virus type 1 (HIV-1) for studying vaccine
mediated and immune correlates of protection. However, knowledge of the structure of the
SIV envelope (Env) glycoprotein is limited, as is knowledge of binding specificity, function
and potential efficacy of SIV antibody responses. In this study we describe the use of a com-
petitive probe binding sort strategy as well as scaffolded probes for targeted isolation of SIV
Env-specific monoclonal antibodies (mAbs). We isolated nearly 70 SIV-specific mAbs
directed against major sites of SIV Env vulnerability analogous to broadly neutralizing anti-
body (bnAb) targets of HIV-1, namely, the CD4 binding site (CD4bs), CD4-induced (CD4i)-
site, peptide epitopes in variable loops 1, 2 and 3 (V1, V2, V3) and potentially glycan targets
of SIV Env. The range of SIV mAbs isolated includes those exhibiting varying degrees of
neutralization breadth and potency as well as others that demonstrated binding but not neu-
tralization. Several SIV mAbs displayed broad and potent neutralization of a diverse panel
of 20 SIV viral isolates with some also neutralizing HIV-27312A. This extensive panel of SIV
mAbs will facilitate more effective use of the SIV non-human primate (NHP) model for
understanding the variables in development of a HIV vaccine or immunotherapy.
Author Summary
An antibody-based approach targeting human immunodeficiency virus (HIV) envelope
(Env) protein may eventually prove to be effective in treating or preventing HIV infection.
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However, before any candidate HIV treatment or vaccine can be tested in humans, it must
first be evaluated in nonhuman primates (NHPs)–the closest living relatives to humans.
Simian immunodeficiency virus (SIV) is the closest available non-chimeric virus—NHP
model for studying and testing HIV vaccines or therapies. The SIV model complements
the simian-human immunodeficiency virus (SHIV) model in distinctive ways, although
less is known about SIV Env-specific antibody responses in NHPs. There are several sites
on HIV Env that are vulnerable to antibody-mediated protection, and here we isolated
and analyzed monoclonal antibodies (mAbs) from NHPs targeting analogous sites on SIV
Env. In particular, we studied mAbs for their ability to bind the viral Env protein and to
block infection of cells by widely divergent strains of SIV. These well-characterized SIV
Env-specific antibodies will allow for more thorough NHP pre-clinical testing of various
antibody-based SIV/HIV vaccine and immunotherapeutic strategies before proceeding to
human clinical trials and may yield unanticipated findings relating to molecular mecha-
nisms underlying the unusual breadth of neutralization observed in HIV-2 infection.
Introduction
Generating protective antibody responses by vaccination is the ultimate goal of an effective
HIV vaccine [1–4]. As such, a number of highly potent bnAbs targeting major sites of HIV-1
Env vulnerability such as the CD4bs [5–8], peptido-glycans of variable loops V1, V2 and V3
[9–12], the membrane-proximal external region (MPER) [13–15] and the gp41-gp120 interface
[16, 17] have been isolated and examined for their potential impact on HIV vaccine design
[18–20]. The specificity and effector functions of protective, non-neutralizing antibodies
(pnnAbs) are likewise being scrutinized for their potential complementary role toward protec-
tion against HIV infection [21–24]. However, recent studies highlight the challenges to devel-
oping an effective HIV-1 vaccine [25–34] and suggest that a better understanding of SIV Env-
specific antibody responses might complement and inform HIV vaccine design. This possibil-
ity is underscored by the protective effects of Env targeted antibodies elicited by adenovirus-
vectored immunogens in SIV protection trials [35–38] and the surprising discovery that HIV-
2, a derivative of SIVsmm, commonly elicits bNabs in natural human infection [39–41]. A bet-
ter understanding of protective SIV Env-specific antibody responses may thus facilitate more
effective use of the SIV challenge model to evaluate candidate vaccines and immunotherapies
before proceeding to costly, time consuming and resource intensive human clinical trials.
Design of a HIV immunogen that can i) focus the antibody response to protective yet sub-
dominant or sterically hindered epitopes, ii) engage Abs encoded by germline B cell receptors
(BCRs) and iii) drive sufficient antibody affinity maturation to generate protective antibody
responses will likely require iterative immunogen design [42]. Additional work will be required
to optimize the antibody specificities and functions, alone or in combination, which are neces-
sary and sufficient to protect against HIV infection. Finally, it will be necessary to assess which
vaccine regimens and adjuvant combinations can achieve the desired germline BCR engage-
ment, affinity maturation, antibody persistence and ultimately, protective efficacy against HIV
challenge. All of these unanswered questions necessitate a relevant NHP model for HIV vac-
cine research
The SHIV—NHP model of HIV infection has been used extensively to study antibody-
mediated correlates of protection [43–46]. Chimeric SHIVs are often constructed by replacing
the envelope gene and additional accessory proteins of the pathogenic molecular clone of SIV-
mac239 with corresponding genes from selected HIV-1 subtypes followed by in vivo passaging
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for enhanced virus replication [47]. Such constructs have proven invaluable for screening can-
didate HIV immunogens and the development of pathogenic SHIV chimeras has allowed for
testing of antibody-mediated protection [48–53]. However, SHIVs have limited genetic diver-
sity [54, 55] compared with SIV challenge stocks that reflect the diversity present in primary
circulating isolates of HIV-1 [56]. Thus, protection against SIV may better estimate the protec-
tive efficacy of a HIV vaccine and may complement the SHIV model used with clinically rele-
vant reagents. Indeed, vaccine protection against acquisition of neutralization resistant SIV
challenges in rhesus macaques suggests a role for antibody-mediated protection [35–37, 57].
However, the epitope specificities and effector functions of SIV-specific antibodies mediating
protection have yet to be fully characterized. Thus, developing reagents to study SIV-specific
antibody responses in NHP can provide an informative model for defining antibody-mediated
correlates of protection.
Our overall goal was to identify SIV-specific antibodies from macaques that may inform the
development of effective HIV antibody-based interventions. Some of the most potent HIV-1
bnAbs target the CD4bs, variable regions V1/V2 and the glycan/V3 loop of gp120 [1]. Given
the paucity of SIV-specific probes, we designed scaffolded probes to isolate SIV V1V2-specific
mAbs and developed a novel competitive probe binding procedure for isolation of SIV mAbs
targeting the CD4bs as well as high-mannose glycans on gp120. Both the scaffolded probes and
competitive probe binding technique were highly efficient for the targeted isolation of SIV-spe-
cific B cells. Subsequent cloning, expression and characterization of individual mAbs identified
many novel, potent mAbs targeting multiple sites of SIV Env vulnerability, including the first
reported SIV CD4bs-specific neutralizing mAbs isolated from SIV-infected rhesus macaques.
Materials and Methods
Indian-origin rhesus macaque specimens
SIV-positive plasma and peripheral blood mononuclear cells (PBMC) were obtained from pre-
viously completed animal study protocols [35, 38, 58] (S1 Table).
Plasmids
A protein scaffold (1JO8) [59] that provides an appropriate hairpin was identified to suitably
incorporate the SIV Env V1V2 region based on stable expression, clash score and solvent acces-
sibility. This scaffold allows V1V2 to be expressed at high yield in a context that maintains
proper conformation of a native V1V2 protomer [60]. A soluble trimeric SIVmac239 gp140
foldon protein expression vector was generated by encoding SIVmac239 from residues 1 thru
722, followed by the foldon trimerization motif as previously described [61]. The following
mammalian expression vectors were used for synthesis of SIV proteins: pcDNA3.1(-) encoding
SIVmac239 gp140 foldon trimer (FT) and pVRC8400 [62] encoding either 1JO8-scaffolded
SIVsmE660.CP3C or SIVsmE660.CR54 V1V2 loop sequences (GenScript). All constructs con-
tained C-terminus 6X His-tag for protein purification followed by an Avi-tag motif for biotiny-
lation. The SIVmac239 ΔV1V2V3 gp120 plasmid encoding gp120 residues 44 to 492 (HXBc2
numbering) with truncations in the V1V2 and V3 regions as in previously reported HIV-1
CoreE gp120 proteins [63], in which residues 124 to 198 in the V1V2 loop and residues 302 to
323 in the V3 loop of SIV gp120 were replaced with GG and GGSGSG linkers, respectively and
kindly provided by Andrés Finzi. Construction of a synthetic gene encoding full-length cyano-
virin-N (CVN) inserted into a pET-26(+) vector (Novagen) has been previously described
[64]. The CD4-Ig plasmid encoding the first two N-terminal domains of the CD4 molecule
which are sufficient for high-affinity gp120 binding fused with the Fc region of human IgG1
was kindly provided by Joseph Sodroski [65].
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Protein production and purification
All SIV proteins and CD4-Ig were expressed by transient transfection of 293Freestyle (293F)
cells in serum-free medium using 293fectin transfection reagent (Invitrogen) according to
manufacturer’s instructions. Cell culture supernatants were harvested 6 days post-transfection,
passed through a 0.22 μm filter to remove any cell debris and supplemented with protease
inhibitor tablets (Roche). All SIV proteins were purified using Ni Sepharose excel affinity
media (GE Healthcare) followed by size exclusion chromatography (SEC) on a HiLoad 16/600
200 pg Superdex column (GE Healthcare). CD4-Ig was purified using a recombinant protein A
affinity column (GE Healthcare) as previously described [66]. Recombinant CVN was pro-
duced as previously reported [67]. Briefly, CVN was expressed in the BL21-DE3 E. coli strain
(New England Biolabs), followed by purification using reversed-phase chromatograpy (Sep-
Pak Vac 35cc (10g) tC18 cartridges, Waters) and gel-filtration (Superdex 75, GE Healthcare) to
ensure separation of monomeric and domain-swapped dimeric CVN.
Targeted isolation of SIV-specific B cells by fluorescence activated cell
sorting (FACS)
Cryopreserved PBMC were thawed and stained with LIVE/DEAD Fixable Violet Dead Cell
Stain (Life Technologies) as previously described [68, 69]. Cells were washed and stained with
an antibody cocktail of CD3 (clone SP34-2, BD Biosciences), CD4 (clone OKT4, BioLegend),
CD8 (clone RPA-T8, BioLegend), CD14 (clone M5E2, BioLegend), CD20 (clone 2H7, BioLe-
gend), IgG (G18-145, BD Biosciences) and IgM (clone G20-127, BD Biosciences) at room tem-
perature in the dark for 20 mins. The cells were washed twice with PBS and subsequently
stained with fluorescently labeled SIV probes to stain for CD4bs-, cyanovirin binding site
(CVNbs)- or V1V2-specific B cells.
For staining of CD4bs-and CVNbs-specific B cells, SIVmac239 gp140 FT was used in com-
bination with 4-fold or 5-fold molar excess of CD4-Ig fusion protein or CVN protein, respec-
tively. Cells were first re-suspended in 200 μl PBS with CD4-Ig:SIVmac239 gp140-PE or CVN:
SIVmac239 gp140-PE, respectively, incubated at room temperature in the dark for 20 mins fol-
lowed by 3 washes with PBS and then re-suspended in 200 μl PBS containing SIVgp140-APC
and incubated further for 20 mins at room temperature in the dark. For staining of V1V2-spe-
cific B cells, cells were re-suspended in 200 μl PBS containing PE-labeled 1JO8 SIVsmE660.
CP3C V1V2 and/or 1JO8 SIVsmE660.CR54 V1V2 and incubated for 20 mins at room temper-
ature in the dark. The stained cells were washed 3 times and re-suspended in 1 ml of PBS,
passed through a 70 μm cell mesh (BD Biosciences) then analyzed and sorted with a modified
3-laser FACSAria cell sorter using the FACSDiva software (BD Biosciences). Probe-positive B
cells were sorted as single cells into wells of a 96-well plate containing lysis solution as previ-
ously described [5]. Flow cytometric data was subsequently analyzed using FlowJo (v9.7.5).
RT-PCR, cloning and expression of immunoglobulin genes
Single B cell RNA was reverse transcribed as previously described [5], diluted 2-fold by addition
of 26 μl nuclease-free water and the cDNA plates were stored at -20°C. Individual rhesus immu-
noglobulin (Ig) heavy (H), light kappa (Lκ) and light lambda (Lλ) chain genes were amplified
by nested PCR using 5 μl cDNA as template. All PCR reactions were performed in 96-well PCR
plates in a total volume of 50 μl. For first round amplification, first-round rhesus-specific PCR
primers (S2–S4 Tables) were used to amplify gene transcripts containing 2 U of HotStar Taq
Plus DNA Polymerase (QIAGEN), 1 μl dNTP-Mix (10 mM each nucleotide) (QIAGEN), 0.5 μg
carrier RNA, 1 mMMgCl2, 1 μl forward primer mix (50 μM each primer), 1 μl reverse primer
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(25 μM each primer), using the following PCR program: 5 min at 94°C; 50 cycles of 30 sec at
94°C, 45 sec at 50°C, 45 sec at 72°C: followed by 10 min at 72°C. One-twentieth the volume of
first-round PCR product was amplified by nested PCR with second-round rhesus-specific PCR
primers (S2–S4 Tables) under the same conditions used for first round PCR. The second round
of PCR was performed for 5 min at 94°C followed by 30 cycles of 30 sec at 94°C, 45 sec at 60°C,
45 sec at 72°C and a final 10 min extension at 72°C. Amplified PCR products were analyzed on
2% agarose gels (Embi-Tec) and positive reactions sequenced directly. PCR products with pro-
ductive Igγ and IgLκ or IgLλ sequence were re-amplified with 3 μl of unpurified first round
PCR product as template and combinations of single gene-specific V and J gene primers incor-
porating unique restriction digest sites. Resulting PCR products were run on a 1% agarose gel
and purified with QIAGENGel Extraction Kit (QIAGEN) and eluted with 25 μl nuclease-free
water (Quality Biolgical). Purified PCR products were digested with appropriate restriction
digest enzymes AgeI, Nhel, BsiWI and ScaI (all from ThermoScientific) before ligation into rhe-
sus Igγ, IgLκ and IgLλ expression vectors containing a murine Ig gene signal peptide sequence
(GenBank accession number DQ407610) and a multiple cloning site upstream of the rhesus Igγ,
Igκ or Igλ constant regions (all 3 expression vectors were kindly provided by Kevin Saunders).
Transcription of these expression vectors is under the influence of human cytomegalovirus
(HCMV) promoter allowing clones to be selected based on resistance to kanamycin. Full-length
IgG was expressed as previously described [5] by co-transfecting 293F cells with equal amounts
of paired heavy and light chain plasmids then purified using Protein A Sepharose beads (GE
Healthcare) according to manufacturer’s instructions.
Immunoglobulin gene family analysis. The IgG heavy chain nucleotide sequences were
assigned to a germline variable gene using local implemented IgBlast (http://www.ncbi.nlm.
nih.gov/igblast/). A new germline V gene database was used for heavy chain germline gene
assignment and somatic mutation calculation [70]. Antibody light chain sequences were com-
pared to the rhesus monkey immunoglobulin germline sequences using IMGT/V-QUEST
from IMGT [71, 72]. Each antibody heavy chain sequence and the assigned germline V gene
were aligned using Muscle and then the nucleotide (nt) divergence was calculated. The heavy-
chain complementary determining region 3 (CDR3) sequence was extracted using the con-
served C at the end of V region and WGXGmotif for heavy chain (X represents any of the 20
amino acids) and the conserved C at the end of V region and FGXG motifs for kappa and
lambda chains. All extracted CDR3 regions were under manual inspection.
Protein and peptide binding and competition assays
Binding of SIV-specific mAbs to purified proteins or synthetic peptides was measured by
enzyme-linked immunosorbent assay (ELISA) as previously described [5]. For CD4bs competi-
tion ELISA, plates were coated with 2 μg/ml SIVmac239 gp140 FT in PBS at 4°C overnight.
After blocking with 200 μl B3T buffer (150mMNaCl, 50mM Tris-HCl, 1mM EDTA, 3.3% fetal
bovine serum, 2% bovine albumin, 0.07% Tween-20), serial dilutions of unlabeled competitor
mAbs were added to captured SIVmac239 gp140 FT in 100 μl B3T buffer for 15 mins prior to
addition of biotinylated CD4-Ig (at a concentration determined to yield O.D. of roughly 1.0–
2.0). Alternatively, competition with sCD4 was performed by addition titrating amounts of
sCD4 to SIVmac239 gp140 FT-coated plates for 15 mins prior to addition of individual mAbs
(at a concentration determined to yield O.D. of roughly 1.0–2.0) and binding was detected by
HRP-conjugated anti-monkey IgG (Rockland Immunochemicals) at a 1:5,000 dilution for 1
hour. Antibody cross-competition ELISA was performed by adding titrations of unlabeled com-
petitor mAbs to SIVmac239 gp140 FT-coated plates for 15 mins prior to addition of individual
biotinylated mAbs (at a concentration determined to yield O.D. of roughly 1.0–2.0). Plates were
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incubated for 1 hr at 37°C, washed 3 times with B3T buffer followed by incubation with strepta-
vidin-horseradish peroxidase (HRP) for 1 hr at 37°C. For peptide competition ELISA, titrations
of peptides were added to SIVmac239 gp140 FT-coated plates for 15 mins prior to addition of
individual mAbs (at a concentration determined to yield O.D. of roughly 1.0–2.0) and binding
detected by HRP-conjugated anti-monkey IgG (Rockland Immunochemicals) as above. The sig-
nal was developed by addition of 3,30,5,50-tetramethylbenzidine (TMB) substrate (SureBlue;
KPL) for 10 min. Reactions were terminated with 1 N sulfuric acid, and the optical density
(OD) was read at 450 nm. The following reagent was obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH: SIVmac239 Env Peptide Set. The following reagent
was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Soluble
Human CD4 from Progenics and sCD4-183 from Pharmacia, Inc. [73]
Viral neutralization and competition assays
Plasmid DNA encoding SIV gp160 was used in combination with a luciferase reporter plasmid
containing the essential HIV structural genes to produce SIV Env pseudoviruses as described
previously [74]. Plasmids encoding SIV gp160 for clones SIVsmE660.11 [75], SIVmac239.cs.23
[76], SIVmac251.6 [76] and SIVmac251.cs.41 [77] were generously provided by David Monte-
fiori. Plasmids encoding SIV gp160 for clones SIVsm (FFv 18Nov04 ENVPL2.1, FJv 15Nov06
ENVPL2.1, FWk 12Aug04 ENVPL4.1 and RSo8 17Jan06 ENVPL1.1) and SIVmac251 (RSo8
17Jan06 ENVPL1.1 and RZj5 9Apr09 ENVPL2.1) were kindly provided by Cynthia Derdeyn
[78]. Full-length infectious molecular clones of transmitted/founder viruses corresponding to
SIVsmm lineage 1 (RM174.V1,V2,V3.tf), 5 (FTq) and “outlier” (SL92b) were derived by meth-
ods previously described [79]. In brief, naïve Indian rhesus macaques were inoculated intrave-
nously with plasma from sooty mangabey monkeys naturally infected with the SIVsmm
lineage 1 or 5 viruses or with a primary lymphocyte culture of SIVsmm SL92b obtained from a
naturally infected sooty mangabey. All three rhesus macaques became productively and chron-
ically infected. Chronic plasma from these three animals was then inoculated intravenously
into three naïve Indian rhesus macaques. Twelve days later, acute infection plasma was col-
lected, plasma viral RNA isolated, viral cDNA generated, full-length T/F SIVsmm sequences
single genome amplified by limiting dilution PCR, and the products molecularly cloned, as
described [79]. IMC sequences (GenBank accession numbers KU182919-23) were identical to
the respective inferred T/F viral genomes, which represent examples of highly diverse natu-
rally-occurring strains of SIVsmm [80]. Virus neutralization was measured using single round
infection of TZM-bl target cells by SIV Env-pseudovirus or replication-competent viruses i.e.
infectious molecular clones (IMC) in the presence of the protease inhibitor indinavir as previ-
ously described [81]. The 50% inhibitory concentration (IC50) was defined as the antibody con-
centration that caused a 50% reduction in relative light units (RLU) compared to virus control
wells after subtraction of background RLU. Half-maximal inhibitory concentration (HalfMax)
was defined as the antibody concentration that caused a 50% reduction in maximum neutrali-
zation for a given mAb while the maximum neutralization (VMax) was defined as the maxi-
mum % neutralization observed over the range of mAb concentrations tested.
Results
Isolation of rhesus antibodies targeting SIV CD4bs by competitive probe
binding
To identify SIV CD4bs-specific B cells, we prepared 2 probes exhibiting differential binding
capacity for CD4bs-specific B cells (Fig 1). A CD4bs-occluded SIVmac239 gp140 FT probe was
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prepared by mixing PE-conjugated SIVmac239 gp140 FT with a 4-fold molar excess of CD4-Ig
fusion protein [66]. An APC-conjugated SIVmac239 gp140 FT served as a CD4bs-accessible
SIVmac239 gp140 probe. SIV CD4bs-specific B cells were identified by first staining cells with
CD4-Ig:SIVmac239 gp140-PE to label all SIV-specific B cells except those blocked by excess
CD4-Ig (Fig 1). After extensive washing to remove unbound CD4-Ig:SIVmac239 gp140-PE
and excess CD4-Ig, cells were stained with SIVmac239 gp140-APC in order to label all SIV-
specific (including CD4bs-specific) B cells (Fig 1). Thus, cells stained negative for CD4-Ig:SIV-
mac239 gp140-PE but positive for SIVmac239 gp140-APC identified putative CD4bs-specific
B cells. B cells binding to both CD4-Ig:SIVmac239 gp140-PE and SIVmac239 gp140-APC
would be expected to bind to gp140 at epitopes outside of the CD4bs.
In combination with a rhesus B cell staining panel (Fig 2A) we used this competitive probe
binding staining procedure to sort 160 putative CD4bs-specific B cells from 4.4 million PBMC
(0.02% of total B cells) from a SIVmac251-infected rhesus macaque (DBM5) [58] (S1 Table;
Fig 2B). Amplification of immunoglobulin heavy and light chain variable regions yielded 37
Fig 1. Targeted isolation of SIV CD4bs-specific B cells. Schematic illustrating competitive probe binding strategy for targeted isolation of CD4bs-specific
B cells. Cells are first stained with a CD4bs-occluded probe (i.e. CD4-Ig:SIVgp140-PE) to label all SIV-specific B cells (red) except those that are specific for
the CD4bs (blue) (Step 1) as shown in FACS plot (top right). After extensive washing to remove unbound CD4-Ig:SIVgp140-PE from first stain (Step 1), cells
are stained with a CD4bs-accessible probe (i.e. SIVgp140-APC in the absence of any competing CD4-Ig) (Step 3). All SIV-specific B cells, including those
specific for the CD4bs, will bind to this probe with putative CD4bs-specific B cells (blue) being positive for SIVgp140-APC and negative for CD4-Ig:
SIVgp140-PE as shown in FACS plot (bottom right).
doi:10.1371/journal.ppat.1005537.g001
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matched heavy and light chain pairs belonging to 13 clonal families. We cloned and expressed
16 mAbs to characterize their binding and neutralization activity (Table 1). Among these 16
mAbs were 3 distinct clonal families including ITS07 and ITS16 mAbs. Rhesus heavy chain V
gene usage of cloned mAbs was mostly restricted to IGHV4 alleles although ITS07 mAbs were
IGHV3. Mutation frequency of heavy and light chain genes within the V region (based on nt
sequence divergence from nearest assigned germline sequence) ranged from 2–11%.
Binding and neutralizing activity of SIV CD4bs-specific mAbs
All putative CD4bs-specific mAbs were tested by ELISA for binding to SIVmac239 gp140 FT
used for cell sorting. While 4 mAbs showed no detectable binding, 12 mAbs bound to SIV-
mac239 gp140 FT with varying affinities (Fig 3). These 12 mAbs also bound to monomeric
SIVmac251.30 gp140 and in most cases to SIVsmE660.CP3C and/or smE660.CR54 gp120s as
well. To evaluate whether mAbs cloned from B cells isolated using our 2-step competitive
probe binding staining protocol were indeed specific for the CD4bs, we re-evaluated binding
of the 12 SIV-specific mAbs to SIVmac239 gp140 FT by competition ELISA with CD4-Ig.
Fig 2. Isolation of CD4bs-specific B cells. A) Gating strategy for isolating rhesus macaque memory B cells i.e. lymphocytes / singlets / Live /
CD3-CD4-CD8-CD14- / CD20+ / IgM- / IgG+ and B) FACS data overlay of individually sorted CD4bs-specific B cells (multicolored) as a percentage of total
memory B cells (gray). C) Competition ELISA of biotinylated CD4-Ig binding to plate-bound SIVmac239 gp140 FT in the presence of individual competing
mAbs graphed as percent inhibition = (OD without competitor—OD with competitor)/ OD without competitor X100. D) ELISA of non-binding mAbs at 5 μg/ml
to plate-bound SIVmac239 gp140 FT in the presence of varying concentrations of sCD4.
doi:10.1371/journal.ppat.1005537.g002
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Binding of CD4-Ig to SIVmac239 gp140 FT was effectively competed by 11 out of 12 mAbs
(Fig 2C) confirming their specificity for the CD4bs.
For those mAbs that failed to bind to SIVmac239 gp140 FT, we hypothesized that residual
CD4-Ig in the staining protocol may have facilitated SIVgp140-APC labeling of CD4-induced
(CD4i)-specific B cells, i.e. binding to an epitope at or near the host cell co-receptor binding
site which is exposed following binding of the primary receptor CD4. We tested whether the
presence of soluble CD4 (sCD4) could facilitate binding of mAbs DBM5-2E10, 2E11, 2B3 and
1A11 to SIVmac239 gp140 FT. The addition of sCD4 had no effect on binding of these mAbs
to SIVmac239 gp140 FT indicating these mAbs bound neither CD4bs- nor CD4i-specific B
cells (Fig 2D). Nonetheless, our sort strategy was highly efficient for isolating CD4bs-specific B
cells, as 11 out of 12 SIV-binding mAbs were CD4bs-specific.
We next assessed neutralizing activity of the 11 CD4bs-specific mAbs by TZM-bl assay
against 4 SIV Env pseudoviruses and the IMC HIV-27312A. All but one CD4bs-specific mAbs
neutralized the highly neutralization-sensitive (tier 1) isolates SIVsmE660.CP3C and SIV-
mac251.H9.15, the moderately neutralization-resistant (tier 2) isolate SIVsmE660.CR54 as well
as the primary isolate HIV-27312A (Fig 4). ITS02 was unique among the CD4bs-specific mAbs
for its strain-specific neutralization of SIVmac251.H9 but not SIVsmE660, SIVmac251.30 or
HIV-27312A. None of the CD4bs-specific mAbs cross-neutralized the highly neutralization-
resistant (tier 3) SIVmac239 (S1 Fig). As previously reported by other groups we observed that
neutralization curves of tier 2 isolates of SIVsmE660 and SIVmac251 plateaued below 100%,
and in some instances, below 50% neutralization despite using clonal, pseudo-typed viruses
[39, 56, 82]. In order to compare the potency of individual mAbs, irrespective of neutralization
plateau levels, we also calculated half-maximal (HalfMax) concentrations (i.e., the concentra-
tion required to achieve half-maximal neutralization) as well as maximum percent neutraliza-
tion (VMax) values (i.e. the maximum % neutralization over the range of mAb concentrations
tested) for individual mAbs (Fig 4). Based on these values, we determined that ITS01 and
Table 1. Genetic characteristics of mAbs isolated from animal DBM5 by CD4bs competition B cell sort. Clonally related mAbs share mAb ID numbers
(i.e. ITS07) with additional numbering to denote individual clonal members (i.e. ITS07.01 and ITS07.02)









ITS01 IGHV4B*02 7% ARGGNIWTGYHSTYFYY IGLV1-14*01 6% QSFDSSVSVQV
ITS02 IGHV4C*01 2% ARDRSSYYTRGLDS IGLV3-1*01 1% QVWDSSSDHYI
ITS07.01 IGHV3M*01 10% VRDGALDCTGSGCWVFDY IGLV5-14*01 5% AIGHSRGYT
ITS07.02 IGHV3M*01 10% VRDGALDCTGSSCWVFDY IGLV5-14*01 4% AIGHSRGYT
ITS08 IGHV4G*02 10% ARTWGIFGLVKNMRFDV IGKV2S17*01 2% MQGLEFPLT
ITS16.01 IGHV4L*02 5% ARHSAGITAAWIGGNRRKTDY IGKV1-12*01 3% QQYNSDPHS
ITS16.02 IGHV4L*02 6% ARHSAGLTAAWIGGRRRKTDY IGKV1-12*01 3% QQYTSDPHS
ITS16.03 IGHV4L*02 6% ARHSAGLTAAWIGGRRRKTDY IGKV1-12*01 4% QQYNSDPHS
ITS19 IGHV4L*03 6% ARHSAGLTAAWIGGSRRKTDY IGKV1-14*01 2% QQRNGYPWT
ITS20 IGHV4L*02 7% ARHSTGLTAAWIGGRRRKIDY IGKV3-5*01 6% QETSDLFT
ITS23 IGHV4F*02 11% ARDETKFGLVVS IGLV1-7*01 5% QSYDTNLRIL
ITS27 IGHV4G*01 11% ARGSNIWTSYYDNWFDV IGLV1S1*01 8% STWDSSLSTGL
DBM5.2E10 IGHV4K*01 6% ASDLLDFWTGYYTGWFDV IGKV1-14*01 3% QQRNGYPWT
DBM5.2E11 IGHV4K*01 6% ASDLLDFWTGYYTGWFDV IGKV1-12*01 4% QQYNSDPHS
DBM5.2B3 IGHV4K*01 6% ASDLLDFWTGYYTGWFDV IGKV2S17*01 2% MQGLEFPLT
DBM5.1A11 IGHV7-B*01 10% ARRGFYWSDRGLDS IGKV3S7*01 9% QQTGDWPLS
doi:10.1371/journal.ppat.1005537.t001
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Fig 3. ELISA binding profiles of SIV-specific mAbs.mAbs cloned from individually sorted SIV Env-specific B cells were evaluated for binding to selected
SIV Env proteins. ELISA binding was categorized as indicated by the legend. ND = not determined.
doi:10.1371/journal.ppat.1005537.g003
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Fig 4. Summary of neutralization potency and cross-reactivity of SIV-specific mAbs. SIV mAbs cloned from targeted B cell sorts to isolate CD4bs-,
CVNbs-and V1V2-specific B cells. Individually sorted SIV CD4bs-, CVNbs- and pre- and post-SIV infection V1V2-specific B cells were evaluated for
neutralization of SIV pseudoviruses and HIV-27312A. Values >50 indicate no neutralization while >50 with asterisk (*) indicates neutralization curve plateaued
below 50%. ND = not determined.
doi:10.1371/journal.ppat.1005537.g004
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ITS20 were also weakly neutralizing against tier 2 SIVmac251.30 and that the potency of indi-
vidual CD4bs mAbs was similar irrespective of the VMax levels.
Antibodies targeting the cyanovirin binding site of SIV
Given the efficiency of our CD4bs competitive binding sort technique, we used the same strat-
egy to isolate antibodies specific for the SIV Env glycan targets of cyanovirin (CVN), a potent
inhibitor of primary and lab-adapted isolates of HIV and SIV [83]. Cyanovirin selectively
binds to Man8 D1D3 and Man9 residues on N-linked glycans present on gp120 [67]. Binding
of CVN also occludes the unique 2G12 neutralization epitope of HIV-1 Env gp120 [84]. We
sorted putative cyanovirin binding site (CVNbs)-specific B cells from 4 SIVsmE660-infected
rhesus macaques (05D247, A4V014, ZB08, ZB42) [35] (S1 Table; Fig 5A) and cloned and
expressed a total of 32 mAbs from these 4 macaques (Table 2). Although 29 out of 32 mAbs
Fig 5. Isolation of CVNbs-specific B cells. A) FACS data overlay of individually sorted CVNbs-specific B cells (multicolored) from 4 SIV-infected rhesus
macaques as a percentage of total memory B cells (gray). B) Summary of competition ELISA of individual mAbs showing percent inhibition: 75–100%
competition (+++); 50–74% competition (++); 25–49% competition (+); <25% competition (-) or increased binding (Enhanced) in the presence of competing
CVN.
doi:10.1371/journal.ppat.1005537.g005
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cloned from the CVNbs competition sort bound to SIVmac239 gp140 FT (Fig 3), only 11 of
these mAbs competed with CVN for binding to gp140 (Fig 5B). Intriguingly, the presence of
CVN rescued the binding of 2 mAbs (ITS56 and ITS57) that failed to bind to SIVmac239
gp140 FT alone suggesting recognition of an epitope on both gp140 and CVN that is only pres-
ent when they are bound together or conformational change(s) induced upon CVN binding
that facilitated binding by these mAbs.
Antibodies isolated by CVNbs competition primarily target nonlinear Env
epitopes
The anti-HIV-1 activity of CVN is reportedly mediated through high affinity interactions with
oligomannose residues suggesting multiple potential binding sites [67]. However, previous
Table 2. Genetic characteristics of mAbs isolated from CVNbs competition B cell sort.











ITS50 05D247 IGHV4L*03 1% ARANYEDDYGYYYKWGGVFDY IGKV1-21*01 1% QQYDDLPYS
ITS51 05D247 IGHV1E*01 4% AASRSGNWYFDL IGLV4S4*01 3% QTWTNGIVL
ITS52 05D247 IGHV4A*02 5% ACPLSGGLNYVLDV IGKV1-21*01 8% LQYTTSPWT
ITS53 05D247 IGHV3W*02 5% ATMDL IGKV2S18*01 9% MQTLQTPFS
ITS54 05D247 IGHV4I*01 4% ARLTVRRLDV IGKV1S24*01 10% QHGYGTPLT
ITS55 05D247 IGHV4L*03 6% AREIGTTIIFRE IGKV1S26*01 4% QQGNSKPFT
ITS56 A4V014 IGHV1I*01 0% ARAQGVYYEDDYGLYFDY IGLV5-7*01 1% TWHGNSKTVL
ITS57 A4V014 IGHV3K*01 7% AMGSGGHSSRDVFDF IGKV1-13*01 2% LQGYDPPYS
ITS58 A4V014 IGHV7B*01 1% ARWDWILQSLDWRVNSLDV IGKV2S5*01 8% MQGTHFPLT
ITS59 A4V014 IGHV3W*01 4% TRDLPYTSWCRGDY IGLV1-15*01 7% AAWDDSLSGVL
ITS60 A4V014 IGHV4F*01 1% ARAFWGYEDDYGYSDNGVYFDS IGLV3-1*01 4% QVWDFSSDHPI
ITS61.01 ZB08 IGHV3K*01 7% VKGMRGDHEVESFEQIIAADPQGDV IGKV2S17*01 5% MQGVEFPWT
ITS61.02 ZB08 IGHV3K*01 8% VKGMRGDIEVESFAQIIAADPAGDV IGKV2S17*01 4% MQGVEFPWT
ITS62 ZB08 IGHV4F*01 11% ASILTGLEFDF IGLV3-1*01 10% QVWDISGDHMF
ITS63 ZB08 IGHV4F*01 8% ASGYSGYSPFDY IGKV1S9*01 12% QHNYGTPWT
ITS64 ZB08 IGHV4F*01 7% ARDSGIAAGEFDY IGKV1-22*01 8% QQYNSSPFT
ITS65 ZB08 IGHV3D*01 2% AGDYDYGSNFLVDY IGKV2S11*01 2% VQVIAFPFT
ITS66.01 ZB08 IGHV3J*01 3% ATGGWLLPFGY IGLV1S1*01 8% GAWDSSLSAGL
ITS66.02 ZB08 IGHV3J*01 5% STGGWLLPFGY IGLV1-13*01 6% GAWDSSLSAGL
ITS67 ZB08 IGHV4F*01 7% ARDGEATFDS IGKV3-8*01 1% QQENSTPT
ITS68 ZB08 IGHV7B*01 2% ARQSRENTGFDY IGKV3S6*01 1% QQESNWSLT
ITS69 ZB08 IGHV1F*02 1% ARTGIQWAQLDLGENYY IGLV3-6*01 5% QVWDSSSKYVL
ITS70 ZB42 IGHV4L*03 6% ARDLVDSEYEVVWFDV IGLV1-13*01 3% GAWDTSLSARV
ITS71 ZB42 IGHV3L*01 5% TRGSGWSEGNEEYFEF IGLV6-5*01 6% QSFDSNTYWL
ITS72 ZB42 IGHV1E*02 5% ARGPRYEDDYGYYDWYFDL IGLV3-1*01 7% QVWDLSSDHVL
ITS73 ZB42 IGHV3L*01 3% TRGNNFWSGSSHYFDY IGLV1-7*01 5% QSYDSSLSVHWV
ITS74 ZB42 IGHV3K*01 2% AKDLPEYCSGSGCYAAPFDY IGKV2-3*01 3% MQALQAPYS
ITS75 ZB42 IGHV4E*02 2% ARHLGGLNYGGRFDF IGKV1-22*01 7% LQYSSSPFT
ITS76 ZB42 IGHV3A*01 4% ARDRSIAAATYYFDY IGLV2S6*01 4% NSYAGSNTFI
ITS77.01 ZB42 IGHV4L*03 6% ARVPGIWFSKYYTFDF IGLV2S9*01 6% GSYREGSTFI
ITS77.02 ZB42 IGHV4L*03 7% ARVPGIWFTNYYVFDF IGLV2S9*01 7% GSYRDGSTFI
ZB42.1H5 ZB42 IGHV4A*02 5% ATIVVAVSAISWFDV IGLV1-10*01 2% SAWDSSLSGVL
doi:10.1371/journal.ppat.1005537.t002
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studies have reported that binding of CVN occludes subsequent binding of the bnAb 2G12 but
not mAbs targeting the V3 and V4 loops, C4 region, CD4bs or CD4i epitopes of HIV-1 indicat-
ing a more defined binding epitope for CVN [84]. To map the SIV epitope(s) targeted by
mAbs isolated by CVNbs competition we also assessed competition between these mAbs and
sCD4. The presence of competing sCD4 did not block binding of any mAbs isolated by CVNbs
competition (Fig 5B). However, one mAb (ITS51) showed enhanced binding to SIVmac239
gp140 FT in the presence of sCD4 (Fig 6A) indicating this mAb likely targets a CD4i site. Addi-
tionally, we tested mAbs from this sort for binding to overlapping SIVmac239 Env 15-mer
peptides. Of 31 mAbs that exhibited SIV gp140 FT binding, 30 were negative for binding to
SIVmac239 Env peptides. Only ITS52 was mapped to a linear peptide sequence near the V3
loop tip (Fig 6B). To further evaluate the epitope binding specificities of mAbs isolated by
Fig 6. Mapping of CVNbs-specific mAbs. A) Competition ELISA of ITS51 and ITS01 (CD4bs) binding to SIVmac239 gp140 FT in the presence or absence
of competing sCD4 or CD4-Ig. B) ELISA binding of ITS52 to SIVmac239 Env 15-mer overlapping peptides. C) ELISA binding curves showing SIVmac239
ΔV1V2V3 gp120 core-binding data of mAbs isolated from CVNbs competition B cell sort and control SIV mAbs.
doi:10.1371/journal.ppat.1005537.g006
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CVNbs competition, we tested binding of individual mAbs to a SIVmac239 ΔV1V2V3 gp120
core protein generated by deletion of the V1V2 loops and truncation of the V3 loop [63]. Of 31
mAbs that bound to SIVmac239 gp140 FT, 7 were also positive for binding to SIVmac239
ΔV1V2V3 gp120 core protein (Fig 6C). As expected, ITS01, a CD4bs-specific mAb also bound
to ΔV1V2V3 gp120 core protein while V2-specific (ITS03) and V3-specific (ITS52) mAbs did
not.
To assess overlapping SIV Env epitope-binding specificities of ITS52 and other mAbs iso-
lated by CVNbs competition, we performed a matrix cross-competition ELISA of CVNbs
mAbs. For 11 CVNbs mAbs tested there were multiple patterns of cross-competition although
most were competed efficiently by multiple mAbs suggesting overlapping specificities (Fig 7).
The ability of ITS01 to compete with ITS51 for binding to SIVmac239 gp140 FT, together with
the sCD4 and CD4-Ig competition data (Fig 6A), indicate that ITS51 targets the CD4i-site of
SIV. Overall, our CVNbs competition sort yielded mAbs targeting the V3 loop, CD4i-site and
ΔV1V2V3 SIVmac239 gp120 core protein.
Antibodies isolated by CVNbs competition neutralize SIV with high
potency
Cyanovirin has been reported to neutralize HIV-1, HIV-2 and SIV primary isolates at low
nanomolar concentrations [67, 83]. To determine whether mAbs isolated by CVNbs competi-
tion could mediate similar virus neutralization breadth and potency, we assessed neutralization
activity of all 32 mAbs isolated by the CVNbs competition sort against a small panel of SIV
Env pseudoviruses and HIV-27312A. Nineteen mAbs were non-neutralizing against all 5 viruses
tested while 13 mAbs neutralized SIVsmE660.CP3C (tier 1), SIVsmE660.CR54 (tier 2) and
SIVmac251.H9 (tier 1) (Fig 4). Of these, 8 mAbs also neutralized SIVmac251.30 (tier 2) and 3
cross-neutralized HIV-27312A. Thus, CVNbs mAbs showed similar virus neutralization cross-
reactivity as CD4bs mAbs; however, the neutralization potency of several CVNbs mAbs was
significantly higher than that of CD4bs mAbs. In some instances 10,000-fold lower IC50
(1,000-fold lower HalfMax) values were obtained for CVNbs mAbs compared with the most
Fig 7. Cross-competition patterns between selected CVNbsmAbs. The effects of unlabeled competitor mAb/protein (listed in the 2nd column) on the
binding of biotin-labeled mAbs (listed across the top) to plate-bound SIVmac239 gp140 FT were measured in duplicate. Values indicate percent inhibition
(average OD reading in the absence of competitor ligand minus average OD reading in the presence of competitor ligand) / average OD value in control wells
expressed as a percentage). Values with insignificant competition are unshaded. Values with low (50–69%), intermediate (70–89%) and high (90%) levels
of competition are indicated as yellow, orange and red boxes, respectively.
doi:10.1371/journal.ppat.1005537.g007
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potent neutralizing CD4bs mAbs (Fig 4). Of note, neutralizing activity correlated with specific-
ity for the CVNbs. All 11 mAbs which efficiently competed with CVN for binding to SIV-
mac239 gp140 FT were neutralizing while of the remaining non-CVNbs-specific mAbs tested,
only ITS56 and ITS57, which required the presence of CVN for binding to SIVmac239 gp140
FT, were neutralizing (Figs 4 and 5B).
Isolation of V1V2-specific antibodies
Both human and non-human primate studies have shown that V1V2 serum IgG binding levels
correlate with protection against HIV/SIV infection [36–38, 85]; therefore, we were also inter-
ested in isolating SIV V1V2-specific B cells. We generated 1JO8-scaffolded SIV V1V2 probes
[60] from tier 1 (SIVsmE660.CP3C) and tier 2 (SIVsmE660.CR54) isolates of the SIVsmE660
challenge swarm used in a recently completed SIV challenge study [38]. Individual fluores-
cently labeled 1JO8-scaffolded SIV V1V2 probes were used to stain and isolate V1V2-specific
B cells from a SIVmac239-vaccinated and SIVsmE660-infected rhesus macaque (S1 Table). We
sorted 36 (0.13% of memory B cells) and 110 (0.16% of memory B cells) SIV V1V2-specific B
cells using 1JO8-scaffolded SIVsmE660.CP3C and SIVsmE660.CR54 V1V2 probes, respec-
tively (Fig 8). A total of 26 mAbs belonging to 9 distinct clonal families were cloned from 146
individually sorted cells and some of these represented identical clones (Table 3). There were
20 unique mAbs: 3 identical clones of ITS03 and 2 identical clones for each of ITS09.01,
ITS10.04, ITS12.01 and ITS30.
Binding and neutralization targets of SIV V1V2-specific mAbs
The 1JO8 SIVsmE660 probes were highly specific since only one of 20 mAbs expressed did not
bind to SIVsmE660 gp120 (Fig 3). The remaining 19 mAbs bound to both SIVsmE660.CP3C
and SIVsmE660.CR54 gp120s with several also binding to SIVmac251.30 gp120 and SIVmac239
gp140 FT. The epitope binding specificities of SIV V1V2 mAbs were assessed by ELISA binding
using overlapping 15-mer SIVmac239 Env peptides spanning the V1V2 region. Peptide map-
ping revealed that ITS06.01 and ITS06.02 bound to several peptides from V1 corresponding to
Env 109–147 (SIVmac239 numbering) (Fig 9A) suggesting a potentially discontinuous epitope
within this region while ITS12.01 and ITS12.02 targeted Env 185–195 (ETWYSADLVCE) (Fig
9B), an epitope at the C-terminus of the V2 loop. Interestingly, although both of these mAbs
bound to this SIVmac239 peptide epitope, neither mAb bound to either SIVmac239 gp140 FT
or SIVmac251.30 gp120. Another linear B cell epitope in V2 was identified by ITS03 and
Fig 8. Isolation SIV V1V2-specific B cells by FACS. FACS data overlays showing individually sorted
(multicolored) 1JO8 SIVsmE660.CP3C (left) and 1JO8 SIVsmE660.CR54 (right) V1V2-specific B cells from a
SIV-infected rhesus macaque as a percentage of total memory B cells (gray).
doi:10.1371/journal.ppat.1005537.g008
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ITS09.01–04 mAbs which bound within Env 173–183 (TGLKRDKKKEY) (Fig 9B). While Env
173–179 was sufficient for binding by ITS03, ITS09.02 and ITS09.04, additional residues were
necessary for binding by ITS09.01 and ITS09.03. All mAbs which did not bind to either SIV-
mac239 gp140 FT or 15-mer peptides were screened for binding to potentially protective
SIVsmE660 15-mer peptide sequences [38]. These mAbs all bound to a 15-mer peptide corre-
sponding to Env 142–156 (ENVINESNPCIKNNS), an epitope that is present in SIVsmE660 but
not SIVmac239 (S2 Fig).
We also assessed neutralizing activity of SIV V1V2-specific mAbs against tier 1 and 2 clonal
isolates of SIVsmE660 and SIVmac251 and HIV-27312A. Despite strong binding to peptide
ENVINESNPCIKNNS, which is present in SIVsmE660.CP3C and SIVsmE660.CR54, only 4 of
9 mAbs specific for this epitope showed weak neutralization against SIVsmE660.CP3C (Fig 4).
Likewise, ETWYSADLVCE-specific mAbs ITS12.01 and ITS12.02 showed strain-specific neu-
tralization of SIVsmE660 isolates but not SIVmac251 or SIVmac239 despite strong binding
to SIVmac239 gp140 FT and linear peptides. In contrast, ETDRWGLTKSI-specific mAbs
ITS06.01, ITS06.02 and ITS13 were cross-neutralizing for SIVsmE660 and SIVmac251 isolates
albeit with varying degrees of breadth and potency. ITS06.02 and ITS13 neutralized tier 1 and
tier 2 isolates of SIVsmE660 and the tier 1 isolate SIVmac251.H9 but not SIVmac251.30 (tier
2). ITS06.01 was the only V1-specific mAb which neutralized both tier 1 and 2 isolates of
SIVsmE660 and SIVmac251. Three V2-specific mAbs targeting the TGLKRDKKKEY epitope
(ITS03, ITS09.03 and ITS09.04) were also neutralizing against the same 4 isolates. None of the
V1V2-specific mAbs neutralized SIVmac239 or HIV-27312A.
Table 3. Genetic characteristics of mAbs isolated from animal 08D038, a SIVmac239-vaccinated, SIVsmE660-challenged rhesusmacaque using
1JO8 SIVsmE660 V1V2-scaffolded probes.












ITS03 E660.CR54 IGHV1J*01 5% ATEGTAAPTAF IGKV4-3*01 2% QQYYSTRLT
ITS06.01 E660.CR54 IGHV3Q*02 8% ARWASRGYFDY IGKV2S17*01 6% MQVLDFPFT
ITS06.02 E660.CP3C IGHV3Q*02 9% ARWASRGYFDS IGKV2S17*01 6% MQVLDFPFT
ITS09.01 E660.CP3C IGHV1J*01 9% ATDPEYNCA IGKV4-3*01 7% QQYLSSPFT
ITS09.02 E660.CR54 IGHV1J*01 5% ATDPEYGCT IGKV4-3*01 3% QQYYRSPFT
ITS09.03 E660.CR54 IGHV1J*01 11% ATDPEYGCT IGKV4-3*01 9% QQYLNAPFT
ITS09.04 E660.CR54 IGHV1J*01 10% ATDPGYGCT IGKV4-3*01 7% QQYLNAPFT
ITS10.01 E660.CP3C IGHV3AB*01 9% TRGSGYNVY IGKV3S3*01 12% QQFAKWPHG
ITS10.02 E660.CR54 IGHV3AB*01 8% TRGSGYNLY IGKV3S3*01 10% QQFANWPHG
ITS10.03 E660.CR54 IGHV3AB*01 9% TRGSGYNVY IGKV3S3*01 12% QQFAKWPHG
ITS10.04 E660.CR54 IGHV3AB*01 9% TRGSGYNIY IGKV3S3*01 10% QQFAKWPHG
ITS12.01 E660.CP3C IGHV3AB*01 9% ISQEVSGSYHYFDY IGKV2S18*01 4% MQALRSPWT
ITS12.02 E660.CR54 IGHV3AB*01 9% ISQEVSGSYHYFDY IGKV2S18*01 4% MQALRSPWT
ITS13 E660.CR54 IGHV3Q*02 13% ARVGVAADKRYSFIDS IGKV2S13*01 14% MQSKEFPFT
ITS30 E660.CP3C IGHV3AB*01 13% TRGSGYNIY IGKV3S3*01 9% QQFSSWPHDV
ITS34.01 E660.CP3C IGHV3AB*01 7% ARGSGCSIY IGKV3-4*01 8% QQYSNWPHG
ITS34.02 E660.CR54 IGHV3AB*01 8% ARGSGCSIY IGKV3-4*01 6% QQYSNWPHG
ITS34.03 E660.CR54 IGHV3AB*01 8% ARGSGCSIY IGKV3-4*01 10% QQYSDWPHG
ITS37 E660.CR54 IGHV3AB*01 VRGSGCNLF IGKV3-4*01 10% QQYNDWPHG
08D038.2C2 E660.CR54 IGHV3J*02 8% TRPYYSGSYYWDY IGKV3-2*01 4% QKYSNSPYS
doi:10.1371/journal.ppat.1005537.t003
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1JO8-scaffolded SIV V1V2 probes identify heterologous vaccine-elicited
B cells
The 1JO8-scaffolded V1V2 probes efficiently labeled V1V2-specific B cells from the chronic
phase of SIV infection; however, we wanted to determine whether these probes could also be
used to isolate low-frequency vaccine-elicited B cells that might be cross-reactive for heterolo-
gous challenge virus. We used the 1JO8 SIVsmE660 V1V2 probes to sort B cells from a pre-
challenge, SIVmac239-vaccinated macaque (ZG12) [38] (S1 Table). In order to maximize probe
binding to heterologous, low frequency pre-challenge memory B cells, we used both 1JO8
SIVsmE660.CP3C and SIVsmE660.CR54 V1V2 probes in combination to sort 74 (0.8% of
memory B cells) SIV V1V2-specific B cells (Fig 10A). We cloned 7 unique mAbs belonging to 6
clonal families (Table 4) and characterized their binding specificities and neutralization activity.
Fig 9. Epitopemapping of SIV-specific mAbs. ELISA testing of SIV V1V2-specific mAbs binding to SIVmac239 Env 15-mer overlapping peptides within A)
V1 and B) V2 regions.
doi:10.1371/journal.ppat.1005537.g009
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Six out of 7 mAbs tested bound to the 1JO8 SIV probes used for cell sorting and to SIVmac239
gp140 FT (Fig 3). Peptide mapping revealed that ZG12-2H10, which failed to bind SIVmac239
gp140 FT, did not bind to any SIVmac239 Env 15-mer overlapping peptides and was non-neu-
tralizing against all viruses tested (Fig 4). Five mAbs were mapped to 1 of 3 epitopes including
two new epitopes not identified by infection-related V1V2 mAbs (Fig 3). Both ITS40 and ITS41
which targeted the V2 epitope EQEQMISCKFNMTGL (Fig 10B), only neutralized tier 1
SIVsmE660.CP3C (Fig 4) while ITS45 targeted Env 101–115 (CVKLSPLCITMRCNK) (Fig
10C) but was non-neutralizing against all isolates tested. Similar to ITS06.01 and ITS06.02
mAbs isolated from chronic SIV infection, ITS42 and ITS44, bound to several peptides from V1
corresponding to Env 109–147 (Fig 10C) and neutralized tier 1 isolates of SIVsmE660 and SIV-
mac251 as well as the tier 2 isolate SIVsmE660.CR54 (Fig 4).
Fig 10. Vaccine-elicited SIV V1V2-specific B cells andmAbs. A) FACS data overlay showing vaccine-elicited (multicolored) 1JO8 SIVsmE660.CP3C and
SIVsmE660.CR54 V1V2-specific B cells from a pre-challenge, SIV vaccinated rhesus macaque as a percentage of total memory B cells (gray). ELISA testing
of vaccine-elicited SIV V1V2-specific B mAbs binding to SIVmac239 Env 15-mer overlapping peptides from B) V2 or C) V1.
doi:10.1371/journal.ppat.1005537.g010
Table 4. Genetic characteristics of mAbs isolated from animal ZG12, a SIV-vaccinated, unchallenged rhesusmacaque using 1JO8 SIV V1V2-scaf-
folded probe.









ITS40 IGHV4L*03 10% VRLSLVGLDS IGLV1S6*01 3% GTWDSSLSAWV
ITS41 IGHV4L*03 11% ARLGLIGVDY IGLV1S6*01 4% GTWDTSLSAWV
ITS42 IGHV2A*01 5% ARSALTGVTSILDS IGLV3S16*01 12% QSADISDNLL
ITS43 IGHV3Q*02 4% ARWGCTGSGCYASFDY IGKV2S17*01 2% MQGLEFPPR
ITS44 IGHV3Q*02 13% VRELFYGGSYFFYN IGLV3S15*01 14% QSLDITGSYPF
ITS45 IGHV3L*01 3% SRGENFWSGYSTEYWFDV IGLV3S16*01 11% QSADFSGNHWI
ZG12.2H10 IGHV3AB*01 8% TRVLYSEDFDY IGKV2S4*01 4% GQGAHWPWT
doi:10.1371/journal.ppat.1005537.t004
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Neutralization breadth and potency of SIV mAbs
While several SIV mAbs were cross-neutralizing for SIVmac251 and SIVsmE660 isolates
tested, the small panel of closely related SIV Env pseudoviruses used to test neutralization
activity limits our ability to assess neutralization breadth of individual SIV mAbs. Therefore,
we tested selected SIV mAbs for neutralization against an additional 15 SIV isolates including
10 SIV Env pseudoviruses and 5 transmitted/founder IMCs (Fig 11). Combined with the
SIVmac251, SIVsmE660 and HIV-27312A viral isolates initially tested (Fig 4), this expanded
21-virus panel (Fig 11A) more closely reflects inter-clade genetic diversity of HIV-1 (Fig 11B)
[80]. Most SIV mAbs tested showed neutralization of multiple SIV strains including neutraliza-
tion of genetically diverse tier 2 and tier 3 SIV isolates. (Fig 12). In general, SIV CD4bs and
CVNbs mAbs displayed greater neutralization breadth than SIV V1V2 mAbs while CVNbs
mAbs were among the most potent (Fig 13, S6–S8 Figs). Neutralization breadth, as measured
by the percentage of SIV/HIV-2 isolates neutralized, was greatest for CD4bs mAbs ITS01 and
ITS20, which neutralized up to 81% and 85% of viruses tested, respectively (Fig 13).
Unsurprisingly, strain-specific mAbs ITS02 (CD4bs) and ITS10.01 (V1) had the lowest neu-
tralization breadth, 20% and 14%, respectively, while the neutralization breadth of CVNbs
mAbs ranged from 62–76%.
Broadly neutralizing mAbs isolated from HIV-1 infected individuals exhibit some unique
features such as high diversity in the variable heavy chain region (VH) genes due to extensive
somatic hypermutation (SHM) [86] and long, protruding CDRH3 sequences [87]. The level
of SHM for HIV-1 bnAbs ranges from 11–32% divergence from putative VH germline nucleo-
tide sequence [88] while HIV-specific antibodies with low or no neutralizing activity display
approximately 9–12% VH sequence divergence from germline [89, 90]. Compared with HIV-1
bnAbs or even rhesus memory B cells, which are approximately 5% divergent from VH
Fig 11. Genetic diversity of SIV and HIV Envs. Phylogenetic tree depicting (A) genetic diversity of SIV Env sequences from a 21 virus panel used to assess
SIV mAb neutralization breadth and potency. (B) Overlay of phylogenetic trees depicting genetic diversity of Env sequences from a multi-clade (indicated in
blue letters) panel of 19 HIV-1 pseudoviruses (blue) and a panel of 20 SIV viral isolates as well as HIV-2 isolate 7312A (red). Tree topology was inferred from
the neighbor-joining method based on ClustalW alignment of protein sequences.
doi:10.1371/journal.ppat.1005537.g011
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Fig 12. Breadth of SIV-specific mAbs.mAbs cloned from individually sorted SIV Env-specific B cells were evaluated for neutralization of SIV
pseudoviruses and transmitted founder (TF) virus IMCs. Values >50 indicate no neutralization while >50* indicates neutralization curve plateaued below
50%. ND = not determined.
doi:10.1371/journal.ppat.1005537.g012
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germline nucleotide sequence [91], the SIV-specific bnAbs isolated here have relatively low lev-
els of SHM. With regard to CDRH3 length, HIV-1 CD4bs bnAbs have relatively short CDRH3
sequences while those targeting quaternary bnAb epitopes of the V1/V2 and V3 loops have
long CDRH3s likely to facilitate penetration of the glycan shield and access to the V1/V2 and
V3 loops [12, 87]. Based on the distribution of CDRH3 length in rhesus naïve B cells [91], we
did not observe unusually long CDRH3 sequences among SIV V1V2-specific mAbs and this
was not altogether surprising since the V1V2 mAbs isolated in this study all targeted linear
peptide epitopes and displayed limited neutralization breadth against our 21 virus panel. By
comparison, some of the SIV CD4bs and CVNbs bnAbs had longer CDRH3 sequences; how-
ever, there is no structural data as yet to support the requirement for long CDRH3s to access
recessed epitopes by SIV bnAbs as is the case for HIV-1 quaternary-preferring bnAbs with
long CDRH3s. In general, neutralizing SIV mAbs did not display some of the unique features
frequently observed in HIV-1 bnAbs.
Discussion
The SIV NHP model for HIV-1 is useful for studying vaccine mediated and immune correlates
of protection but little is known about binding or neutralizing epitopes on SIV Env. Our goal
was to isolate and characterize SIV Env-specific mAbs that might facilitate effective use of this
NHP model for understanding the variables in development of a HIV vaccine or immunother-
apy. We demonstrate the use of a novel competitive probe binding strategy for the targeted iso-
lation of SIV Env-specific mAbs from rhesus macaques and present a detailed assessment of
nearly 70 SIV mAbs targeting the CD4bs, CD4i-site, CVNbs and V1, V2 and V3 loops of SIV
Env. We characterized individual SIV mAbs with regard to immunoglobulin genetics, epitope
specificity, peptide and protein binding as well as virus neutralization breadth and potency.
Various studies have characterized neutralization epitopes of SIV using murine, guinea pig,
rabbit and goat antisera [92, 93] as well as murine- [94–98] or rhesus-derived [99–102] SIV-
specific mAbs. The range of epitopes described includes SIV mAbs targeting linear epitopes in
variable loops 1–4 [38, 92, 93, 95–97, 100–102] and conformational epitopes involving the
V3-V4 region [100, 101] as well as those overlapping or proximal to the CD4bs [95, 98] and
co-receptor binding site [95]. However, SIV-specific mAbs isolated to date have been produced
exclusively from hybridomas [94–98], EBV-transformed B cells [99–101] or phage display
Fig 13. Neutralizing activity of SIV mAbs against a 21-virus panel. The percentage of viruses neutralized with half maximal neutralization (HalfMax)
<50 μg/ml and <1 μg/ml as well as the median HalfMax values for viruses neutralized with HalfMax < 50 μg/ml.
doi:10.1371/journal.ppat.1005537.g013
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[102]. Ours is the first study to describe the targeted isolation of SIV epitope-specific B cells
from rhesus macaques using direct and indirect binding to novel SIV probes.
Given the paucity of reagents for the targeted isolation of SIV-specific B cells we developed
a simple competitive probe binding strategy to sort CD4bs-directed B cells from which we
cloned multiple SIV CD4bs mAbs. Nearly 70% of mAbs isolated by this method were con-
firmed to target the CD4bs—significantly improved efficiency as compared to the isolation of
HIV CD4bs mAbs using HIV-1 resurfaced stabilized core 3 (RSC3) protein [5]. By substituting
CVN in place of CD4-Ig as competitor ligand, we were able to modify the target cell population
to sort CVNbs-specific B cells. We subsequently cloned several mAbs from sorted B cells and
confirmed their specificity for the CVNbs, thereby validating this competitive probe binding
strategy as a powerful technique for the targeted isolation of SIV-specific B cells. Based on the
simplicity and efficiency of our competitive probe binding sort strategy we propose that this
method may be preferable to the use of engineered probes for targeted isolation of epitope-spe-
cific B cells—at least epitopes for which probe binding ligands are available. With this method,
even antibodies could serve as competitive ligands for Env trimer probes to facilitate isolation
of additional antibodies targeting a given epitope without the need for time-consuming probe
development. Competitive ligands cross-reactive for divergent HIV/SIV Env probes could
extend the applicability of this competitive sort strategy to diverse strains of HIV/SIV. This
simple and effective competitive probe sort technique may also prove useful for the isolation of
virus-specific B cells in general. The 1JO8-scaffolded SIV V1V2 probes we designed and tested
were also remarkably efficient at labeling both high frequency infection-related and low fre-
quency vaccine-elicited SIV V1V2-specific B cells. Several of the SIV V1V2 epitopes targeted
by mAbs isolated with the 1JO8-scaffolded SIV V1V2 probes have previously been identified
following isolation of B cells using other strategies [103] thereby validating the use of these
probes for targeted isolation of V1V2-specific B cells. Overall, the ability to efficiently target
SIV mAbs of defined specificities will increase the usefulness and relevance of the SIV model
for studying the induction and maturation of virus-specific B-cells.
Many SIV-specific B cell epitopes previously reported have been identified using murine
derived or HIV-2-specific mAbs exhibiting cross-reactivity with SIV [103]. Here, we provide
the most extensive study of SIV Env-specific mAbs isolated from rhesus macaques including
the first reported rhesus SIV CD4bs-specific mAbs. Of nearly 70 SIV Env-specific mAbs iso-
lated the most broadly neutralizing SIV mAbs were CD4bs-specific, likely due to the conserved
nature of the CD4bs for maintaining functional contact with its primary receptor CD4. Indeed,
cross-reactivity of HIV-2 CD4bs mAbs for SIV has previously been reported [39]. Among the
CD4bs mAbs, ITS02 was notable for its strain-specific neutralization of SIVmac251 (tier 1)
only, suggesting that despite strong competition with CD4-Ig for binding to SIV Env, its epi-
tope is likely proximal to rather than directly at the CD4bs.
As with the CD4bs mAbs, CVNbs mAbs also displayed considerable neutralization breadth
against our 21-virus panel; however, only a fraction of CVNbs mAbs cross-neutralized HIV-2.
Given the lack of information regarding epitope specificity of most of the CVNbs mAbs it is
unclear whether the lack of cross-reactivity for HIV-2 is due to sequence, glycosylation or
other conformational differences between SIV and HIV-2 or some combination thereof. The
single CVNbs mAb for which we determined peptide-binding specificity within the V3 loop,
neutralized 62% of isolates tested despite minimal sequence variation in this epitope among
SIVs and HIV-27312A. Of note, several CVNbs mAbs were significantly more potent than either
the SIV CD4bs- or V1V2-directed mAbs. Among these were 2 clonally related CVNbs mAbs
(ITS61.01 and ITS61.02) with extraordinarily high potency and unusually long (25 residues)
heavy chain complementarity determining region 3 (CDRH3) loops similar to V2 and V3 gly-
can reactive mAbs that are among the most potent HIV-1 bnAbs [9, 12, 104–106]; however,
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these high potency mAbs do not target V2 or V3 glycans since they bind to V1,V2,V3-deleted
SIV gp120 core protein.
Compared with the relatively minor sequence variation between the V3 loops of SIV/HIV-
2, there is considerable sequence diversity between SIV and HIV-2 within the V1 and V2 loops
and this was reflected by the fact that all SIV V1V2 mAbs isolated were non-neutralizing
against HIV-2. Interestingly, all SIV V1V2 mAbs were mapped to linear peptide epitopes
although it is unclear whether this was due primarily to the 1JO8-scaffolded probe used for iso-
lating B cells and/or the immunization history or immune response of animals used for cell
sorting. Among the major sites of HIV-1 Env vulnerability, the V1V2 loops are of particular
interest for an HIV vaccine based on results of both human and NHP vaccine efficacy trials
showing that levels of V1V2-specific serum binding, but not neutralizing activity, directly cor-
relate with resistance to HIV/SIV infection [38, 85]. Among the SIV V1V2 mAbs isolated we
identified both neutralizing as well as binding, non-neutralizing mAbs which may serve as use-
ful reagents for delineating the role of V1V2-binding mAbs towards protection against infec-
tion. An important caveat is the presence of two conserved cysteine residues in the V2 region
of most SIV and HIV-2 strains, which are absent in all HIV-1 strains [107]. These twin-cyste-
ine residues may form a disulfide bond that contributes to Env trimer stabilization since twin-
cysteine mutants exhibit decreased gp120 association with the Env trimer cell-cell fusion and
virus infectivity. Future studies will need to address whether the conserved twin-cysteine motif
may contribute to structural or functional differences between SIV/HIV-2 and HIV-1 and any
potential impact on V1V2-directed mAb responses in SIV/HIV-2.
Overall, we isolated multiple SIV mAbs directed against major targets of SIV Env vulnera-
bility analogous to bnAb targets of HIV-1, namely the CD4bs, peptide epitopes of V1/V2 and
V3 loops and potentially glycan targets of SIV Env (Fig 14). We did not isolate SIV mAbs tar-
geting the V4 loop although it is possible that some of the SIV mAbs from the CVNbs sort may
map to this region. Targeted isolation of V4-specific SIV mAbs could prove useful as the V4
region of SIV contains immunodominant epitopes and represents an early target for neutraliz-
ing mAbs [108, 109]. Compared with HIV-1 bnAb targets, we were unable to isolate quater-
nary-structure-preferring SIV-specific mAbs. While a pre-fusion SIV trimer structure has yet
Fig 14. Neutralization epitopes of SIV Envmodeled onto the 3D structure of HIV-1 BG505 SOSIP.664 trimer. Pre-fusion HIV-1 BG505 trimer structure
(PDB ID: 4TVP) is displayed in ribbon representation with red for CD4-binding-site-directed antibody specificities (VRC01-, b12-, CD4-, and HJ16-like),
purple for 8ANC195-like, green for V1V2-directed (PG9-like), blue for glycan-V3 specificities (PGT128- and 2G12-like), orange for 35O22-like specificities,
and green-yellow for PGT151-like specificities. Epitope targets of SIV Env neutralizing mAbs are shown as spheres with red for CD4-binding-site-, green for
V1V2-, and blue for V3-directed specificities. Top (left) and side (right) views are shown.
doi:10.1371/journal.ppat.1005537.g014
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to be determined, it is likely that the SIV foldon trimer and 1JO8-scaffolded probes used for B
cell sorting adopt an open quaternary conformation, analogous to HIV-1 soluble, uncleaved
trimers [32, 110], which likely precluded us from isolating SIV quaternary-structure-preferring
neutralizing mAbs. In fact, structural analysis of vaccine-induced HIV CD4bs-directed mAbs
has revealed that despite high affinity binding to soluble Env ligands such as foldon trimers,
such mAbs display a suboptimal angle of approach resulting in non-bnAbs with limited
breadth and lack of neutralization activity against neutralization-resistant isolates such as JRFL
[111]. Additional methods will be needed to isolate SIV bnAbs targeting quaternary epitopes,
V1, V2 or V3 glycans, the immunodominant V4 region, the gp120-gp41 interface and MPER
region.
The range of SIV mAbs isolated includes binding, non-neutralizing mAbs as well as strain-
specific and cross-neutralizing mAbs exhibiting varying degrees of neutralization breadth and
potency. We isolated SIV mAbs from SIV-vaccinated, pre-challenge as well as SIV-vaccinated
and infected macaques. All but one of the SIV mAb epitopes identified from the latter showed
high sequence similarity among SIV isolates tested making it difficult to determine whether
individual mAb responses were elicited by the immunogen or the challenge virus Env. Only
one of the SIV mAb epitopes identified (Env 142–15) was present in the SIVsmE660 challenge
virus but not the SIVmac239 immunogen indicating that mAbs targeting this region were elic-
ited following infection.
Comparison of the neutralization profiles for individual mAbs and corresponding serum
samples for most animals revealed that the isolated mAbs recapitulated the breadth of serum
neutralization in most cases (S9 Fig). In addition, the neutralization plateau effect reported for
some HIV-1-specific mAbs [16] was also evident for neutralization curves of SIV mAbs against
tier 2 isolates of both SIVmac251 and SIVsmE660, irrespective of mAb specificity. While differ-
ences in Env trimer glycosylation may explain incomplete neutralization by glycan-dependent
mAbs [112], emerging data suggests conformational heterogeneity of Env trimers even within
a clonal pseudovirus population may account for neutralization curve plateaus for glycan-inde-
pendent mAbs [38, 113]. Other groups have also observed striking heterogeneity in neutraliza-
tion sensitivities between SIV isolates [78, 82]. While the majority of clones within the well-
characterized SIVsmE660 vaccine challenge stock are highly neutralization sensitive, approxi-
mately 10–25% exhibit an intermediate neutralization sensitivity phenotype and 10% are out-
right neutralization resistant [82]. Despite the broad range of epitopes targeted by SIV mAbs
isolated and their capacity to bind SIVmac239 gp140 FT protein, none were able to neutralize
the highly neutralization resistant SIVmac239. This was not wholly unexpected since sera from
these animals also failed to neutralize SIVmac239 (Fig 12). This discrepancy between binding
and neutralizing activity against a particular Env protein/virus has also been observed for HIV-
1 CD4bs-directed mAbs and is thought to be result from inefficient recognition of cognate epi-
tope due to quaternary packing conformational constraints in the context of functional, mem-
brane-bound trimer despite high affinity binding to soluble Env ligands [111, 114, 115].
With the development of our novel competitive probe binding sort strategy and subsequent
isolation and detailed characterization of nearly 70 SIV Env-specific mAbs we now have the
necessary reagents with which to study immune and vaccine mediated correlates of protection
in the SIV NHP challenge model of HIV-1. This includes testing of SIV bnAb passive immuni-
zation alone or as an adjunct to antiretroviral therapy (ART) by direct injection or gene ther-
apy. As well, the binding, non-neutralizing SIV Env-specific mAbs identified here will serve as
useful reagents for delineating the contribution of antibody-dependent cellular cytotoxicity
(ADCC), antibody-dependent cell-mediated viral inhibition (ADCVI) and additional FcR-
mediated activities toward control and/or prevention of HIV/SIV infection. Finally, use of
additional probes and methods to isolate SIV-specific B cells will facilitate more thorough and
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rigorous pre-clinical evaluation of mAb-based immunotherapies for treatment and/or preven-
tion of SIV infection in NHPs.
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